(NASDAQ: RLYB) Rallybio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.67%.
Rallybio's earnings in 2026 is -$8,978,000.On average, 5 Wall Street analysts forecast RLYB's earnings for 2026 to be -$26,056,410, with the lowest RLYB earnings forecast at -$28,656,285, and the highest RLYB earnings forecast at -$20,439,304. On average, 3 Wall Street analysts forecast RLYB's earnings for 2027 to be -$19,423,687, with the lowest RLYB earnings forecast at -$18,661,973, and the highest RLYB earnings forecast at -$19,994,972.
In 2028, RLYB is forecast to generate -$16,833,862 in earnings, with the lowest earnings forecast at -$16,173,710 and the highest earnings forecast at -$17,328,975.